Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo
AUTOR(ES)
Maruno, Kaname
FONTE
The National Academy of Sciences
RESUMO
Small-cell lung carcinoma (SCLC) is an aggressive, rapidly growing and metastasizing, and highly fatal neoplasm. We report that vasoactive intestinal peptide inhibits the proliferation of SCLC cells in culture and dramatically suppresses the growth of SCLC tumor-cell implants in athymic nude mice. In both cases, the inhibition was mediated apparently by a cAMP-dependent mechanism, because the inhibition was enhanced by the adenylate cyclase activator forskolin and the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine in proportion to increases in intracellular cAMP levels, and the inhibition was abolished by selective inhibition of cAMP-dependent protein kinase. If confirmed in clinical trials, this antiproliferative action of vasoactive intestinal peptide may offer a new and promising means of suppressing SCLC in human subjects, without the toxic side effects of chemotherapeutic agents.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24380Documentos Relacionados
- Treatment of Small-Cell Lung Cancer
- Cholera toxin inhibits signal transduction by several mitogens and the in vitro growth of human small-cell lung cancer.
- A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
- Human lung small-cell carcinoma contains bombesin.
- A unique cell-surface protein phenotype distinguishes human small-cell from non-small-cell lung cancer.